New therapeutic strategies for squamous cell cancer and adenocarcinoma.

about

New therapeutic strategies for squamous cell cancer and adenocarcinoma.

Item

http://www.wikidata.org/entity/Q38151816

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

New therapeutic strategies for squamous cell cancer and adenocarcinoma.

@en

type

Item

label

New therapeutic strategies for squamous cell cancer and adenocarcinoma.

@en

prefLabel

New therapeutic strategies for squamous cell cancer and adenocarcinoma.

@en

P1476

New therapeutic strategies for squamous cell cancer and adenocarcinoma.

@en

P2093

Bas P L Wijnhoven

http://www.w3.org/2001/XMLSchema#string

Daniel Vallböhmer

http://www.w3.org/2001/XMLSchema#string

Eelke L A Toxopeus

http://www.w3.org/2001/XMLSchema#string

Jelle P Ruurda

http://www.w3.org/2001/XMLSchema#string

Kimberly Perez

http://www.w3.org/2001/XMLSchema#string

Marc Schiesser

http://www.w3.org/2001/XMLSchema#string

Mark J Krasna

http://www.w3.org/2001/XMLSchema#string

Paul Schneider

http://www.w3.org/2001/XMLSchema#string

Peter S N van Rossum

http://www.w3.org/2001/XMLSchema#string

Valter Nilton Felix

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Cancer statistics, 2012

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview.

Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.

P304

213-225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NYAS.12247

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

1300

http://www.w3.org/2001/XMLSchema#string

P50

Richard van Hillegersberg

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24117644

http://www.w3.org/2001/XMLSchema#string